GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (STU:NKB2) » Definitions » Other Gross PPE

TG Therapeutics (STU:NKB2) Other Gross PPE : €8.6 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is TG Therapeutics Other Gross PPE?

TG Therapeutics's Other Gross PPE for the quarter that ended in Mar. 2024 was €8.6 Mil.

TG Therapeutics's quarterly Other Gross PPE declined from Sep. 2023 (€9.3 Mil) to Dec. 2023 (€8.8 Mil) and declined from Dec. 2023 (€8.8 Mil) to Mar. 2024 (€8.6 Mil).

TG Therapeutics's annual Other Gross PPE increased from Dec. 2021 (€9.8 Mil) to Dec. 2022 (€10.2 Mil) but then declined from Dec. 2022 (€10.2 Mil) to Dec. 2023 (€8.8 Mil).


TG Therapeutics Other Gross PPE Historical Data

The historical data trend for TG Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Other Gross PPE Chart

TG Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.63 9.74 9.80 10.22 8.77

TG Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 9.42 9.25 8.77 8.59

TG Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


TG Therapeutics (STU:NKB2) Business Description

Traded in Other Exchanges
Address
3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully-integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics (STU:NKB2) Headlines

No Headlines